2. Search Result
Search Result
Results for "

dependent

" in MedChemExpress (MCE) Product Catalog:

2581

Inhibitors & Agonists

9

Screening Libraries

21

Fluorescent Dye

36

Biochemical Assay Reagents

238

Peptides

1

MCE Kits

60

Inhibitory Antibodies

324

Natural
Products

181

Recombinant Proteins

126

Isotope-Labeled Compounds

78

Antibodies

21

Click Chemistry

52

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-143770
    Cap-dependent endonuclease-IN-16

    		Influenza Virus Infection
    Cap-dependent endonuclease-IN-16 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-16 is a pyridone polycyclic derivative. Cap-dependent endonuclease-IN-16 has the potential for the research of influenza (extracted from patent CN112778330A, compound 15A) .
    Cap-dependent endonuclease-IN-16
  • HY-143776
    Cap-dependent endonuclease-IN-22

    		Influenza Virus Infection
    Cap-dependent endonuclease-IN-22 is a potent cap-dependent endonuclease (CEN) inhibitor .
    Cap-dependent endonuclease-IN-22
  • HY-P3944
    Calmodulin Dependent Protein Kinase Substrate

    		CaMK Neurological Disease
    Calmodulin Dependent Protein Kinase Substrate is a Ca 2+- and calmodulin (CaM)-dependent protein kinase (CaMK) substrate peptide. Calmodulin Dependent Protein Kinase Substrate is a synthetic peptide substrate for protein kinases .
    Calmodulin Dependent Protein Kinase Substrate
  • HY-143781
    Cap-dependent endonuclease-IN-26

    		Influenza Virus Infection
    Cap-dependent endonuclease-IN-26 is a cap-dependent endonuclease (CEN) inhibitor with an IC50 of 286 nM. Cap-dependent endonuclease-IN-26 shows antiviral activity against many influenza A and B strains .
    Cap-dependent endonuclease-IN-26
  • HY-144065
    Cap-dependent endonuclease-IN-19

    		Influenza Virus Infection
    Cap-dependent endonuclease-IN-19 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-19 is a spirocyclic pyridone derivative. Cap-dependent endonuclease-IN-19 has strong inhibitory effect on RNA polymerase activity of A virus (extracted from patent CN111410661A, compound 1) .
    Cap-dependent endonuclease-IN-19
  • HY-143749
    Cap-dependent endonuclease-IN-6

    		Influenza Virus Infection
    Cap-dependent endonuclease-IN-6 (compound 13) is a cap-dependent endonuclease (CEN) inhibitor. Cap-dependent endonuclease-IN-6 shows inhibition against influenza virus (EC50=38.21 nM) .
    Cap-dependent endonuclease-IN-6
  • HY-144068
    Cap-dependent endonuclease-IN-25

    		Influenza Virus Infection
    Cap-dependent endonuclease-IN-25 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-25 is a macrocyclic pyridotriazine derivative. Cap-dependent endonuclease-IN-25 has the potential for the research of viral infections caused by viruses belonging to the Orthomyxoviridae family (extracted from patent WO2020075080A1, compound 4) .
    Cap-dependent endonuclease-IN-25
  • HY-144066
    Cap-dependent endonuclease-IN-21

    		Influenza Virus Infection
    Cap-dependent endonuclease-IN-21 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-21 inhibits the replication of influenza virus. ap-dependent endonuclease-IN-21 has the potential for the research of influenza virus infection (influenza A) (extracted from patent WO2021233302A1, compound 8B or 8A) .
    Cap-dependent endonuclease-IN-21
  • HY-143768
    Cap-dependent endonuclease-IN-14

    		Influenza Virus Infection
    Cap-dependent endonuclease-IN-14 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-14 inhibits the replication of influenza virus. Cap-dependent endonuclease-IN-14 has the potential for the research of viral infections caused by influenza viruses (extracted from patent CN113620948A, compound 1-c) .
    Cap-dependent endonuclease-IN-14
  • HY-143769
    Cap-dependent endonuclease-IN-15

    		Influenza Virus Infection
    Cap-dependent endonuclease-IN-15 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-15 inhibits the replication of influenza virus. Cap-dependent endonuclease-IN-15 has the potential for the research of viral infections caused by influenza viruses (extracted from patent CN113226327A, compound c-1) .
    Cap-dependent endonuclease-IN-15
  • HY-144067
    Cap-dependent endonuclease-IN-23

    		Influenza Virus Infection
    Cap-dependent endonuclease-IN-23 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-23 inhibits the replication of influenza virus. ap-dependent endonuclease-IN-23 has the potential for the research of influenza virus infection (influenza A) (extracted from patent WO2021233302A1, compound 8A or 8B) .
    Cap-dependent endonuclease-IN-23
  • HY-143762
    Cap-dependent endonuclease-IN-12

    		Influenza Virus Infection
    Cap-dependent endonuclease-IN-12 (EXP-35) is a potent Cap-dependent endonuclease inhibitor with low cytotoxicity. Cap-dependent endonuclease-IN-12 shows inhibitory activity against H1N1 .
    Cap-dependent endonuclease-IN-12
  • HY-143750
    Cap-dependent endonuclease-IN-7

    		Influenza Virus Infection
    Cap-dependent endonuclease-IN-7 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-7 Inhibits the synthesis of viral mRNA and eventually inhibits virus proliferation. Cap-dependent endonuclease-IN-7 has the potential for the research of viral infections (including influenza A, influenza B and influenza C) (extracted from patent WO2020177715A1, compound 5)
    Cap-dependent endonuclease-IN-7
  • HY-163621
    Cap-dependent endonuclease-IN-28

    		Influenza Virus Infection
    Cap-dependent endonuclease-IN-28 (Compound 11) is a potent cap-dependent endonuclease (CEN) inhibitor. Cap-dependent endonuclease-IN-28 inhibits CEN of TOSV, ANDV, and LACV viruses with IC50 values ​​of 2.4, 0.5, and 4 μM, respectively .
    Cap-dependent endonuclease-IN-28
  • HY-162242
    Cap-dependent endonuclease-IN-27

    		Influenza Virus Infection
    Cap-dependent endonuclease-IN-27 (Compound 8) is an orally active potent cap-dependent endonuclease (CEN) inhibitor. Cap-dependent endonuclease-IN-27, an antiviral agent, shows activity against influenza B virus. Cap-dependent endonuclease-IN-27 has inhibitory activity against IFV A/WSN/33 (H1N1) polymerase (EC50 = 12.26 nM) .
    Cap-dependent endonuclease-IN-27
  • HY-143766
    Cap-dependent endonuclease-IN-13

    		Influenza Virus Infection
    Cap-dependent endonuclease-IN-13 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-13 has the potential for the research of influenza virus infection (only influenza A) (extracted from patent WO2021180147A1, compound I-1) .
    Cap-dependent endonuclease-IN-13
  • HY-143752
    Cap-dependent endonuclease-IN-8

    		Influenza Virus Infection
    Cap-dependent endonuclease-IN-8 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-8 inhibits replication of orthomyxoviruses (including influenza A, influenza B and influenza C) (extracted from patent CN111410661A, compound I-196) .
    Cap-dependent endonuclease-IN-8
  • HY-P3943
    Calmodulin Dependent Protein Kinase Substrate Analog

    		CaMK Neurological Disease
    Calmodulin Dependent Protein Kinase Substrate Analog is a Ca 2+- and calmodulin (CaM)-dependent protein kinase (CaMK) substrate peptide. Calmodulin Dependent Protein Kinase Substrate Analog is a synthetic peptide substrate for protein kinases .
    Calmodulin Dependent Protein Kinase Substrate Analog
  • HY-143744
    Cap-dependent endonuclease-IN-3

    		Influenza Virus Infection
    Cap-dependent endonuclease-IN-3 is a potent inhibitor of cap-dependent endonuclease (CEN). Not only can Cap-dependent endonuclease-IN-3 inhibit influenza virus well, but also has lower cytotoxicity, better in vivo agent kinetic properties and in vivo pharmacodynamic properties. Cap-dependent endonuclease-IN-3 has the potential for the research of influenza A and influenza B infection (extracted from patent WO2019141179A1, compound VI-1) .
    Cap-dependent endonuclease-IN-3
  • HY-143755
    Cap-dependent endonuclease-IN-9

    		Influenza Virus Infection
    Cap-dependent endonuclease-IN-9 is a potent inhibitor of cap-dependent endonuclease (CEN). Not only can Cap-dependent endonuclease-IN-9 inhibit influenza virus well, but also has lower cytotoxicity, better in vivo agent kinetic properties and in vivo pharmacodynamic properties. Cap-dependent endonuclease-IN-9 has strong inhibitory effect on RNA polymerase activity of A virus (extracted from patent CN112521386A, compound VI-1) .
    Cap-dependent endonuclease-IN-9
  • HY-143743
    Cap-dependent endonuclease-IN-2

    		Influenza Virus Infection
    Cap-dependent endonuclease-IN-2 is a potent inhibitor of cap-dependent endonuclease (CEN). Not only can Cap-dependent endonuclease-IN-2 inhibit influenza virus well, but also has lower cytotoxicity, better in vivo agent kinetic properties and in vivo pharmacodynamic properties. Cap-dependent endonuclease-IN-2 has strong inhibitory effect on RNA polymerase activity of A virus (extracted from patent WO2019052565A1, compound 28) .
    Cap-dependent endonuclease-IN-2
  • HY-143775
    Cap-dependent endonuclease-IN-20

    		Influenza Virus Infection
    Cap-dependent endonuclease-IN-20 is a cap-dependent endonuclease (CEN) inhibitor. Cap-dependent endonuclease-IN-20 shows antiviral activity against influenza virus A/Hanfang/359/95 (H3N2) with IC50 of 4.82 μM (CN112940009A; DSC801) .
    Cap-dependent endonuclease-IN-20
  • HY-143771
    Cap-dependent endonuclease-IN-17

    		Influenza Virus Infection
    Cap-dependent endonuclease-IN-17 is a cap-dependent endonuclease (CEN) inhibitor. Cap-dependent endonuclease-IN-17 shows antiviral activity against influenza virus A/Hanfang/359/95 (H3N2) with IC50 of 1.29 μM (CN112898346A; DSC701) .
    Cap-dependent endonuclease-IN-17
  • HY-143747
    Cap-dependent endonuclease-IN-5

    		Influenza Virus Infection
    Cap-dependent endonuclease-IN-5 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-5 inhibits influenza virus well, and/or has lower cytotoxicity, better in vivo pharmacokinetic properties and in vivo pharmacodynamic properties (extracted from patent WO2020078401A1, compound 13-1) .
    Cap-dependent endonuclease-IN-5
  • HY-E70419
    PQQ-Dependent glucose dehydrogenase, microorganism

    		Others Others
    PQQ-Dependent glucose dehydrogenase, microorganismyes PQQnovel nanostructure platform for fluorescence analysis of glucose dehydrogenase-dependent glycogenase. Fluorescence signals were generated under ultraviolet excitation at a wavelength (365 nm).
    PQQ-Dependent glucose dehydrogenase, microorganism
  • HY-143757
    Cap-dependent endonuclease-IN-10

    		Influenza Virus Infection
    Cap-dependent endonuclease-IN-10 is a potent inhibitor of cap-dependent endonuclease (CEN). Not only can Cap-dependent endonuclease-IN-10 inhibit influenza virus well, but also has lower cytotoxicity, better in vivo pharmacokinetic and in vivo pharmacodynamic properties, and better hepatic microsomal stability. Cap-dependent endonuclease-IN-10 has the potential for the research of viral infections (including influenza A, influenza B and influenza C) (extracted from patent WO2021129799A1, compound 1-1) .
    Cap-dependent endonuclease-IN-10
  • HY-P1874
    Calmodulin-Dependent Protein Kinase II (281-309)

    		Calmodulin Neurological Disease
    Calmodulin-Dependent Protein Kinase II (281-309) is a peptide of calcium/calmodulin-dependent protein kinase II (CaM-kinase II) .
    Calmodulin-Dependent Protein Kinase II (281-309)
  • HY-P1479
    Calmodulin-Dependent Protein Kinase II (290-309)

    		Autophagy CaMK Neurological Disease
    Calmodulin-Dependent Protein Kinase II (290-309) is a potent CaMK antagonist with an IC50 of 52 nM for inhibition of Ca2+/calmodulin-dependent protein kinase II .
    Calmodulin-Dependent Protein Kinase II (290-309)
  • HY-P1479A
    Calmodulin-Dependent Protein Kinase II(290-309) acetate

    		Autophagy CaMK Neurological Disease
    Calmodulin-Dependent Protein Kinase II (290-309) acetate is a potent CaMK antagonist with an IC50 of 52 nM for inhibition of Ca2+/calmodulin-dependent protein kinase II .
    Calmodulin-Dependent Protein Kinase II(290-309) acetate
  • HY-118141
    BMS-194449

    		Adrenergic Receptor Metabolic Disease
    BMS-194449 is a beta 3 receptor agonist with the Ki value of 160 nM. BMS-194449 can be used for study of obesity and non-insulin dependent diabetes .
    BMS-194449
  • HY-P10499
    [Ala286]-Calmodulin-Dependent Protein Kinase II (281-302)

    		CaMK Others
    [Ala286]-Calmodulin-Dependent Protein Kinase II (281-302) is a modified fragment of calcium/calmodulin-dependent protein kinase II that contains the active domain of CaMKII and has an alanine substitution at position 286. [Ala286]-Calmodulin-Dependent Protein Kinase II (281-302) can be used to develop more potent CaMKII inhibitors .
    [Ala286]-Calmodulin-Dependent Protein Kinase II (281-302)
  • HY-D1122
    Janus green B

    		Fluorescent Dye Others
    Janus green B is a supravital stain. Janus green B staining reaction is oxygen dependent, and is reversibly inhibited by cyanide. Janus green B has been used for staining peripheral nerves in live insects, lymphatic vessels of rabbits and mitochondria .
    Janus green B
  • HY-77537
    7-Deazaxanthine

    7DX

    		 Thymidylate Synthase Cardiovascular Disease
    7-Deazaxanthine (7DX) is an inhibitor of thymidine phosphorylase (TPase). 7-Deazaxanthine inhibits TPase reaction in a concentration-dependent manner with an IC50 value of 40 μM. 7-Deazaxanthine also has a significant angiogenesis inhibitory effect .
    7-Deazaxanthine
  • HY-P2541
    GIP (1-30) amide, porcine

    		Insulin Receptor Metabolic Disease
    GIP (1-30) amide, porcine is a full glucose-dependent insulinotropic polypeptide (GIP) receptor agonist with high affinity equal to native GIP(1-42) . GIP (1-30) amide, porcine is a weak inhibitor of gastric acid secretion and potent stimulator of insulin.
    GIP (1-30) amide, porcine
  • HY-P2541A
    GIP (1-30) amide, porcine TFA
    1 Publications Verification

    		 Insulin Receptor Metabolic Disease
    GIP (1-30) amide, porcine TFA is a full glucose-dependent insulinotropic polypeptide (GIP) receptor agonist with high affinity equal to native GIP(1-42) . GIP (1-30) amide, porcine is a weak inhibitor of gastric acid secretion and potent stimulator of insulin.
    GIP (1-30) amide, porcine TFA
  • HY-10195
    Ruboxistaurin
    5+ Cited Publications

    LY333531

    		 PKC Metabolic Disease
    Ruboxistaurin (LY333531) is an orally active, selective PKC beta inhibitor (Ki=2 nM). Ruboxistaurin exhibits ATP dependent competitive inhibition of PKC beta I with an IC50 of 4.7 nM. Ruboxistaurin inhibits PKC beta II with an IC50 of 5.9 nM .
    Ruboxistaurin
  • HY-P3186A
    NAD-dependent Glucose dehydrogenase

    GDH-NAD

    		 Endogenous Metabolite Metabolic Disease
    NAD-dependent Glucose dehydrogenase (GDH-NAD) ((EC 1.1.1.47)) 是一种 NAD 依赖的氧化还原酶。Glucose dehydrogenase (GDH) 催化 β-D-葡萄糖氧化为 β-D-葡糖酸-1,5-内酯，同时将辅助因子 NADP + 还原为 NADPH，或在较小程度上还原 NAD+ 到 NADH。Glucose dehydrogenase (GDH) 接受 NAD + 和 NADP + 作为辅助因子，可用于 NADH 和 NADPH 的再生。
    NAD-dependent Glucose dehydrogenase
  • HY-E70014
    FAD-dependent glucose dehydrogenase

    FAD-GDH; Glucose 1-dehydrogenase

    		 Endogenous Metabolite Others
    FAD-dependent glucose dehydrogenase (EC 1.1.5.9), or glucose dehydrogenase (FAD)/Pseudomonas glucose dehydrogenase. Glucose 1-dehydrogenase is an enzyme used as a regeneration cofactor to convert glucose and NAD(P) into NAD(P)H and gluconic acid .
    FAD-dependent glucose dehydrogenase
  • HY-120303
    LY269415

    		Lipoxygenase Inflammation/Immunology
    LY269415, is an anti-oxidant agent, is a potent and orally active iron dependent lipid peroxidation and 5-lipoxygenase enzyme inhibitor. LY269415 has anti-inflammatory effects .
    LY269415
  • HY-10195R
    Ruboxistaurin (Standard)

    LY333531 (Standard)

    		 PKC Metabolic Disease
    Ruboxistaurin (Standard) is the analytical standard of Ruboxistaurin. This product is intended for research and analytical applications. Ruboxistaurin (LY333531) is an orally active, selective PKC beta inhibitor (Ki=2 nM). Ruboxistaurin exhibits ATP dependent competitive inhibition of PKC beta I with an IC50 of 4.7 nM. Ruboxistaurin inhibits PKC beta II with an IC50 of 5.9 nM .
    Ruboxistaurin (Standard)
  • HY-W141932
    N-Stearoylglycine

    Stearoylglycine; N-Octadecanoylglycine

    		 Endogenous Metabolite Others
    N-stearoylglycine is a lipid and has a small ionizable polar headgroup whose charge is pH dependent and whose amide moiety can form H-bonded network between adjacent molecules in ordered films .
    N-Stearoylglycine
  • HY-164764
    ADX61623

    		Estrogen Receptor/ERR Endocrinology
    ADX61623 is a potent follicle stimulating hormone (FSH) receptor (FSHR) negative allosteric modulator (NAM). ADX61623 shows luteinizing hormone receptor (LH-R) activity and is not active on thyroid-stimulating hormone (TSH) receptors. ADX61623 can be used for the study of estrogen dependent disease .
    ADX61623
  • HY-120767
    Linzagolix choline

    KLH-2109 choline; OBE-2109 choline

    		 GnRH Receptor Inflammation/Immunology Cancer
    Linzagolix choline (KLH-2109 choline) is a non-peptide gonadotropin-releasing hormone (GnRH) antagonist with oral activity. Linzagolix choline inhibits the release of endogenous gonadotropins such as luteinizing hormone LH and follicle-stimulating hormone FSH by binding to the GnRH receptor within the pituitary gland. This inhibition results in a reduction in the production of sex hormones such as estrogen and progesterone, which in turn affects the course of sex hormone-dependent diseases. Linzagolix choline can be used in the study of sex hormone-dependent diseases such as endometriosis and uterine fibroids .
    Linzagolix choline
  • HY-150576
    c-Met-IN-13

    		c-Met/HGFR Cancer
    c-Met-IN-13 is a potent c-Met inhibitor with an IC50 value of 2.43 nM. c-Met-IN-13 shows excellent cytotoxicity for cancer cells. c-Met-IN-13 shows antiproliferative activity in a concentration- and time- dependent manner. c-Met-IN-13 has the potential for the research of cancer .
    c-Met-IN-13
  • HY-P2026
    A 71915

    		Natriuretic Peptide Receptor (NPR) Cardiovascular Disease
    A 71915 is a highly potent and competitive natriuretic peptide receptor A (ANP, NPRA) antagonist (pKi= 9.18). A 71915 displaces [ 125I]ANP dose dependently, with a Ki of 0.65 nM. A71915( pA2= 9.48) against rat ANP-induced cGMP production in NB-OK-1 cells .
    A 71915
  • HY-156579
    WRN inhibitor 3

    		DNA/RNA Synthesis Cancer
    WRN inhibitor 3 (example 110), a cyclic vinyl sulfone compound, is a Wemer Syndrome ATP dependent helicase enzyme (WRN) inhibitor. WRN inhibitor 3 can be used for the research of cancer .
    WRN inhibitor 3
  • HY-156580
    WRN inhibitor 4

    		DNA/RNA Synthesis Cancer
    WRN inhibitor 4 (example 107), a cyclic vinyl sulfone compound, is a Wemer Syndrome ATP dependent helicase enzyme (WRN) inhibitor. WRN inhibitor 4 can be used for the research of cancer .
    WRN inhibitor 4
  • HY-P99381
    XmAb 5592
    1 Publications Verification

    		 Transmembrane Glycoprotein Cancer
    XmAb 5592 is a humanized, Fc-engineered anti-HM1.24 antibody with enhanced binding to FcγRIIIa and FcγRIIa receptors, augments HM1.24-specific multiple myeloma (MM) cells lysis in vitro via antibody-dependent cellular cytotoxicity (ADCC) and antibody dependent cellular phagocytosis (ADCP) .
    XmAb 5592
  • HY-156581
    WRN inhibitor 5

    		DNA/RNA Synthesis Cancer
    WRN inhibitor 5, a cyclic vinyl sulfone compound, is a Wemer Syndrome ATP dependent helicase enzyme (WRN) inhibitor. WRN inhibitor 5 can be used for the research of cancer, including cancers characterized by microsatellite instability (MSI) and/or defective DNA mismatch repair system (dMMR) .
    WRN inhibitor 5
  • HY-101544
    ARQ 069

    		FGFR Cancer
    ARQ 069, an analog of ARQ 523, inhibits FGFR in an enantiospecific manner. ARQ 069 targets the unphosphorylated, inactive forms of FGFR1/FGFR2 kinases (IC50s of 0.84 μM and 1.23 μM, respectively). ARQ 069 inhibits FGFR1/FGFR2 autophosphorylation (IC50s of 2.8 and 1.9 μM, respectively) through a mechanism in a non-ATP competitive dependent manner .
    ARQ 069

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: